8-K: Cabaletta Bio Announces Second Quarter 2024 Financial Results and Provides Clinical Program Update

Cabaletta Bio reported its second quarter 2024 financial results and provided a business update, highlighting progress in its clinical programs and manufacturing strategy.

Summary

• Cabaletta Bio announced its financial results for the second quarter ended June 30, 2024, and provided a business update on August 8, 2024.
• The company has enrolled nine patients in the RESET clinical development program as of August 5, 2024, with four new enrollments since June.
• They now have 22 U.S. clinical sites actively enrolling patients.
• Cabaletta anticipates releasing additional clinical data from the RESET-Myositis and RESET-SLE trials, as well as initial data from the RESET-SSc and RESET-MG trials in the second half of 2024.
• Initial clinical and translational data from the first patients in the RESET-Myositis and RESET-SLE trials were presented at EULAR in June 2024.
• A lupus nephritis patient experienced a Grade 4 ICANS toxicity, which resolved quickly, and the study was recommended to proceed without delay.
• New agreements with Lonza and Cellares will support the next stage of manufacturing to expand clinical supply and prepare for commercial scaling of CABA-201.
• As of June 30, 2024, Cabaletta had $203.2 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the first half of 2026.
• Research and development expenses were $23.4 million for the three months ended June 30, 2024, compared to $11.8 million for the same period in 2023.
• General and administrative expenses were $6.9 million for the three months ended June 30, 2024, compared to $4.1 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical progress, manufacturing advancements, and a solid financial position. The company is executing its strategy effectively, and the initial data is promising. The only negative is the increase in expenses and a single patient experiencing a toxicity, which was quickly resolved.

Positives

• Patient enrollment in the RESET clinical program is increasing, with four new patients enrolled since June.
• The company has expanded its clinical trial network to 22 sites in the U.S.
• Initial clinical data for CABA-201 showed good tolerability and the expected CAR T cell expansion and B cell depletion.
• The company has secured manufacturing agreements with Lonza and Cellares to support clinical and commercial supply.
• Cabaletta has a strong cash position of $203.2 million, expected to fund operations into the first half of 2026.
• The company has appointed a new Chief Technology Officer with significant cell therapy experience.
• The independent data monitoring committee recommended the study to proceed without delay after a patient experienced a dose-limiting toxicity.
• The company is implementing protocol modifications to improve patient safety.

Negatives

• A lupus nephritis patient experienced a Grade 4 ICANS toxicity, although it resolved rapidly.
• Research and development expenses increased significantly to $23.4 million for the quarter, compared to $11.8 million in the same period last year.
• General and administrative expenses also increased to $6.9 million for the quarter, compared to $4.1 million in the same period last year.
• Cash, cash equivalents and short-term investments decreased from $241.2 million as of December 31, 2023 to $203.2 million as of June 30, 2024.

Risks

• The company is subject to risks related to regulatory filings and potential clearance.
• There is a risk that signs of biologic activity or persistence may not inform long-term results.
• Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of CABA-201 is not guaranteed.
• The results observed with the similarly-designed construct employed in academic publications may not be indicative of the results they seek to achieve with CABA-201.
• Modifications to trial design or approach may not have the intended benefits and the trial design may need to be further modified.
• There are risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected.
• Delays related to assessment of clinical trial results are possible.
• Unexpected safety or efficacy data observed during clinical studies could impact the program.
• The company is subject to risks related to volatile market and economic conditions and public health crises.
• Cabaletta's ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and Fast Track Designation is not guaranteed.
• There are risks related to Cabaletta's ability to protect and maintain its intellectual property position.
• The company is subject to risks related to fostering and maintaining successful relationships with its collaboration and manufacturing partners.
• Uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates exist.
• There is a risk that any one or more of Cabaletta's product candidates will not be successfully developed and/or commercialized.
• The initial or interim results of preclinical studies or clinical studies may not be predictive of future results in connection with future studies.

Future Outlook

Cabaletta expects its cash, cash equivalents, and short-term investments as of June 30, 2024, will enable it to fund its operating plan into the first half of 2026. The company anticipates additional clinical data readouts in the second half of 2024 and is focused on advancing its manufacturing strategy.

Management Comments

• Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta, stated that they have seen increased enrollment and additional clinical sites open since presenting positive initial clinical and translational data at the EULAR 2024 Congress in June.
• Steven Nichtberger, M.D., also mentioned that they look forward to sharing additional clinical data on CABA-201 in the second half of this year.
• The CEO noted that they have recently advanced their manufacturing strategy for CABA-201 through a new CDMO agreement with Lonza and by expanding their existing fully automated manufacturing collaboration with Cellares.
• The CEO believes that with the momentum and milestones achieved in the second quarter and recent period, they are well positioned to realize their vision of developing and launching the first curative targeted cell therapy for patients with autoimmune diseases.

Industry Context

This announcement highlights Cabaletta's progress in the competitive field of cell therapy for autoimmune diseases. The company's focus on developing targeted therapies and scaling manufacturing is in line with industry trends. The positive initial clinical data and manufacturing advancements position Cabaletta as a notable player in this space.

Comparison to Industry Standards

• The use of a 4-1BB co-stimulatory domain in CABA-201 is similar to the construct used in academic studies at Erlangen University, which have shown promising results in autoimmune diseases.
• The reported B cell depletion and clinical improvements are consistent with the outcomes observed in academic studies using similar CD19-CAR T therapies.
• The expansion profile of CABA-201 is comparable to that of BCMA-CAR T products in multiple myeloma, where the number of target cells is more similar to autoimmune disease than to B cell leukemias and lymphomas.
• The company's manufacturing strategy, including partnerships with Lonza and Cellares, aligns with industry best practices for scaling up cell therapy production.
• The reported cash runway into the first half of 2026 is a positive sign for the company's financial stability and ability to execute its clinical programs, which is comparable to other companies in the biotech space.

Management Changes

Stakeholder Impact

• Shareholders should view the clinical progress and manufacturing advancements positively.
• Employees may be encouraged by the company's growth and progress.
• Patients with autoimmune diseases may benefit from the development of new therapies.
• Suppliers and partners may see increased business opportunities with Cabaletta.
• Creditors should be reassured by the company's strong cash position.

Next Steps

• Cabaletta plans to share additional clinical data on CABA-201 in the second half of 2024.
• The company will continue to advance its manufacturing strategy for CABA-201.
• Cabaletta will continue to enroll patients in its ongoing clinical trials.
• The company will implement protocol modifications to improve patient safety.

Key Dates

Keywords

Cabaletta Bio, CABA-201, CAR T-cell therapy, autoimmune diseases, clinical trials, RESET program, manufacturing, Lonza, Cellares, financial results, ICANS, B cell depletion